Collegium Pharmaceutical (COLL) Cash from Investing Activities (2015 - 2026)

Collegium Pharmaceutical has reported Cash from Investing Activities for 12 years, with the latest figure at -$502.6 million in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 17141.54% year-over-year to -$502.6 million in Q2 2026; TTM through Jun 2026 was -$551.9 million, a 101.92% decrease from a year earlier, with the FY2025 full-year figure at -$63.5 million, up 77.92% from the prior year.
• Cash from Investing Activities was -$502.6 million for Q2 2026 at Collegium Pharmaceutical, down from $1.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $1.6 million in Q1 2026, with the low at -$572.2 million in Q1 2022.
• Average Cash from Investing Activities over 5 years is -$83.2 million, with a median of -$10.7 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities slumped 133586.21% in 2022, then soared 116.81% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$940000.0 in 2022, then sank by 2569.89% to -$25.1 million in 2023, then soared by 53.13% to -$11.8 million in 2024, then plunged by 70.63% to -$20.1 million in 2025, then slumped by 2404.32% to -$502.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$502.6 million (Q2 2026), $1.6 million (Q1 2026), and -$20.1 million (Q4 2025), per Business Quant data.